Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 6 Carcinoma, Non-Small-Cell Lung 6 Stomach Neoplasms 5 Lymphoma, Non-Hodgkin 5 Carcinoma, Renal Cell 5 Pancreatic Neoplasms 3 Ovarian Neoplasms 3 Neoplasms 3 Neoplasm Metastasis 3 Colorectal Neoplasms 3 Carcinoma, Merkel Cell 3 Triple Negative Breast Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Skin Neoplasms 2 Esophageal Neoplasms 2 Carcinoma, Transitional Cell 2 Adenocarcinoma of Lung 2 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Solid Tumor 1 Small Cell Lung Carcinoma 1 Sarcoma 1 Recurrence 1 Prostatic Neoplasms 1 Ovarian Cancer Metastatic 1 Neuroblastoma 1 Multiple Myeloma 1 Microsatellite Instability 1 Lymphoma, Follicular 1 Lymphoma 1

Interventions

fludarabine 1 aldesleukin 1 Interleukin-2 1 Cyclophosphamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Ovarian Cancer Metastatic × aldesleukin × Clear all

NCT04389229 2020-12-16

OVSTAR

Immetacyte Ltd

Phase 1/2 Withdrawn

Ovarian Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡